MetaVia Inc. — Director's Dealing 2023

Jul 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2023-07-27

Reporting Person: KOVEN ANDREW I (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-07-27	Common Stock	A	87500	—	Acquired	87500	Direct
2023-07-27	Common Stock	A	12500	—	Acquired	100000	Direct

Footnotes

F1: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. Per the terms of the Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the reporting person's retirement or other separation form service with the Issuer or death, whichever is earlier.

F2: 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service.

F3: Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.